Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...

Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...

Add Yahoo as a preferred source to see more of our stories on Google. Chinese health experts are raising concerns about the growing interest among parents to use synthetic human growth hormones on ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new ...

(Reuters) -The U.S. Food and Drug Administration has approved Pfizer Inc and partner OPKO Health Inc's treatment for growth hormone deficiency in children, the companies said on Wednesday. The ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved long-acting once-weekly somatrogon for children with growth hormone deficiency. Somatrogon was ...

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

NEW YORK (Reuters Health) - Type 2 diabetes is eight and a half times more common among children in the United States treated with growth hormone than among kids who are not on the hormone treatment, ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...